Wednesday, January 29, 2014 Daily Archives

EMD Millipore Expands its EMPROVE Raw Materials Portfolio to 400 Products

EMD Millipore • Portfolio now includes 400 active pharmaceutical ingredients, excipients and biopharmaceutical materials • Application-specific documentation streamlines pharmaceutical process and reduces qualification costs • Increases patient safety by avoiding errors inherent in manual documentation Billerica, MA – EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced the expansion of its EMPROVE® raw materials portfolio to 400 active pharmaceutical ingredients, excipients and biopharmaceutical materials. The products offer comprehensive application-specific documentation in addition to superior quality,…